Therapeutically active compounds and their methods of use

Abstract

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

1 . A compound of formula I or a pharmaceutically acceptable salt, tautomer, isotopologue or hydrate thereof, wherein: 
       
         
           
           
               
               
           
         
         R 1  is optionally substituted C 4 -C 6  carbocyclyl; 
         each R 2  and R 3  is independently selected from optionally substituted aryl or optionally substituted heteroaryl; 
         R 4  is alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, or optionally substituted heteroaralkyl; 
         ring A is 4-6 membered non-aromatic ring having 0-1 additional heteroatoms selected from N, O or S, wherein ring A is optionally substituted with one or two R 5  groups; 
         each R 5  is independently halo; —CF 3 ; —CN; —OR 6 ; —N(R 6 ) 2 ; —C(O)C 1 -C 4  alkyl; C 1 -C 4  haloalkyl; C 1 -C 4  alkyl optionally substituted with —OR 6  or —N(R 6 ) 2 ; —O—C 1 -C 4  alkyl optionally substituted with halo, —OR 6  or —N(R 6 ) 2 ; —SO 2 N(R 6 ) 2 ; —SO 2 (C 1 -C 4  alkyl); —NR 6 SO 2 R 6 ; C 3 -C 5  carbocyclyl optionally substituted with one or two R 6  groups; —O—(C 3 -C 6  carbocyclyl optionally substituted with one or two R 6  groups); 5-6 membered heteroaryl; —C 1 -C 4  alkyl-C(O)O—C 1 -C 4  alkyl; or —C(O)O—C 1 -C 4  alkyl; or 
         each R 6  is independently H or C 1 -C 3  alkyl. 
       
     
     
         2 . The compound of  claim 1 , wherein:
 R 1  is C 4 -C 6  carbocyclyl optionally substituted with one to three R 7  groups;   each R 2  and R 3  is independently selected from aryl or heteroaryl, wherein said aryl or heteroaryl is independently optionally substituted with one to three R 7  groups;   R 4  is alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, wherein said aryl, heteroaryl, aralkyl, and heteroaralkyl are each independently optionally substituted with one to three R 7  groups;   ring A is 4-6 membered non-aromatic ring having 0-1 additional heteroatoms selected from N, O or S, wherein ring A is optionally substituted with one or two R 5  groups;   each R 5  and R 7  is independently halo; —CF 3 ; —CN; —OR 6 ; —N(R 6 ) 2 ; —C(O)C 1 -C 4  alkyl; C 1 -C 4  haloalkyl; C 1 -C 4  alkyl optionally substituted with —OR 6  or —N(R 6 ) 2 ; —O—C 1 -C 4  alkyl optionally substituted with halo, —OR 6  or —N(R 6 ) 2 ; —SO 2 N(R 6 ) 2 ; —S(O)—C 1-4  alkyl; —SO 2  (C 1 -C 4  alkyl); —NR 6 SO 2 R 6 ; C 3 -C 5  carbocyclyl optionally substituted with one or two R 6  groups; —O—(C 3 -C 6  carbocyclyl optionally substituted with one or two R 6  groups); 5-6 membered heteroaryl; —C 1 -C 4  alkyl-C(O)O—C 1 -C 4  alkyl; or —C(O)O—C 1 -C 4  alkyl; or   each R 6  is independently H or C 1 -C 4  alkyl.   
     
     
         3 . The compound of  claim 1  or  2 , wherein each R 2  and R 3  is independently aryl optionally substituted with one to three R 7  groups. 
     
     
         4 . The compound of  claim 1  having formula II-a, 
       
         
           
           
               
               
           
         
       
       wherein R 10  is CR 11  or N; and R 11  is —F, —SO 2 NH 2 , —SO 2 CH 3 , —S(O)CH 3 , —CN, methoxy, —OCH 2 OH, —CH 2 OH, —SO 2 N(CH 3 ) 2 , —SO 2 NHCH 3 , —NHSO 2 CH 3 , —CH 2 CH 2 OH, —N(CH 3 ) 2 , t-butyl, cyclopropyl, —C(OH)(CH 3 ) 2 , —OCF 3 , —OCHF 2 , —O-cyclopropyl, -1-methyl-cyclopropyl, or pyrazolyl. 
     
     
         5 . The compound of  claim 1  or  2 , wherein R 1  is C 4  or C 6  cycloalkyl optionally substituted with one to two R 7  groups and R 7  associated with R 1  is halo. 
     
     
         6 . The compound of  claim 5 , wherein R 1  is 
       
         
           
           
               
               
           
         
       
     
     
         7 . The compound of  claim 5 , wherein ring A is: 
       
         
           
           
               
               
           
         
       
       wherein 
       
         
           
           
               
               
           
         
       
       denotes ring A's attachment to the amide moiety of formula and 
       
         
           
           
               
               
           
         
       
       denotes ring A's attachment to R 4 ; and each member of ring A is optionally substituted with one or two R 5  groups. 
     
     
         8 . The compound of  claim 7 , wherein ring A is: 
       
         
           
           
               
               
           
         
       
     
     
         9 . The compound of  claim 7 , wherein R 4  is aryl or heteroaryl, each aryl or heteroaryl is optionally substituted with one to three R 7  groups. 
     
     
         10 . The compound of  claim 9 , wherein R 4  is: 
       
         
           
           
               
               
           
         
       
       wherein each member of R 4  is optionally substituted with one or two R 7  groups and each R 7  is independently F, Cl, methyl, CF 3 , CN, OMe, or N(R 6 ) 2 . 
     
     
         11 . The compound of  claim 10 , wherein R 4  is: 
       
         
           
           
               
               
           
         
       
       wherein R 100  is H, methyl, C 1 , CF 3 , CN, OCH 3 , or N(R 6 ) 2  and R 101  is H, F or methyl. 
     
     
         12 . The compound is selected from any one of compounds from Table 1. 
     
     
         13 . A pharmaceutical composition comprising a compound of  claim 1 ; and a pharmaceutically acceptable carrier. 
     
     
         14 . The composition of  claim 13 , further comprising a second therapeutic agent useful in the treatment of cancer. 
     
     
         15 . A method of treating a cancer characterized by the presence of an IDH1 mutation, wherein the IDH1 mutation results in a new ability of the enzyme to catalyze the NAPH-dependent reduction of α-ketoglutarate to R(−)-2-hydroxyglutarate in a patient, comprising the step of administering to the patient in need thereof a composition of  claim 13 . 
     
     
         16 . The method of  claim 15 , wherein the IDH1 mutation is an IDH1 R132H or R132C mutation. 
     
     
         17 . The method of  claim 15 , wherein the cancer is selected from glioma (glioblastoma), acute myelogenous leukemia, melanoma, non-small cell lung cancer (NSCLC), cholangiocarcinomas, chondrosarcoma, myelodysplastic syndromes (MDS), myeloproliferative neoplasm (MPN), colon cancer in a patient. 
     
     
         18 . The method of  claim 17 , further comprising administering to the patient in need thereof a second therapeutic agent useful in the treatment of cancer.